It is a single drug that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon
It contributes to the health of the body and the lungs, and also plays a central role in the protection of cells against cellular damage induced by oxidative stress, but also in the detoxification of xenobiotics and drug metabolism
[6] Large observational studies and meta-analyses examining GLP-1 receptor agonists, including semaglutide, suggest that the absolute risk increase attributable to the medication is small, with no clear increased risk versus comparator treatments
Because of that uncertainty, the FDA labelling recommends weighing the benefits of breastfeeding alongside the mother's need for Zepbound and any possible effects on the baby
The recent approval of two anti-amyloid monoclonal antibody therapieslecanemab and donanemabfor early, symptomatic AD has generated much interest regarding the effectiveness of these therapies in slowing cognitive decline
